56 related articles for article (PubMed ID: 3150273)
1. Antiinflammatory effect of a lipoxygenase inhibitor (FLM 5011) in severe active myocarditis.
Geissler W; Förster A; Schewe T; Rapoport SM; Slapke J; Meyer R; Romaniuk P; Reisinger I
Biomed Biochim Acta; 1988; 47(10-11):S311-4. PubMed ID: 3150273
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive treatment in autoreactive myocarditis--results from a controlled trial.
Maisch B; Schönian U; Hengstenberg C; Herzum M; Hufnagel G; Bethge C; Bittinger A; Neumann K
Postgrad Med J; 1994; 70 Suppl 1():S29-34. PubMed ID: 7971646
[TBL] [Abstract][Full Text] [Related]
3. [Biotransformation of the lipoxygenase inhibitor 2-hydroxy-5-methyl-laurophenone-oxime (FLM 5011)].
Langner A; Rentsch C; Nerlich C; Rittner I; Kühn H; Schewe T; Franke P
Pharmazie; 1996 Jun; 51(6):403-9. PubMed ID: 8767850
[TBL] [Abstract][Full Text] [Related]
4. [Improvement of the absorption of the active substance 2'-hydroxy-5'-methyllaurophenoxamine (FLM 5011) with prodrugs and preparations].
Tscheuschner C; Neubert R; Fürst W; Lücke L; Fries G
Pharmazie; 1993 Sep; 48(9):681-4. PubMed ID: 8234402
[TBL] [Abstract][Full Text] [Related]
5. [Immunosuppressive treatment of chronic myocarditis].
Wimmer M; Proll E; Salzer-Muhar U; Schlemmer M; Strigl E
Wien Klin Wochenschr; 1988 Oct; 100(19):658-63. PubMed ID: 3239064
[TBL] [Abstract][Full Text] [Related]
6. The protective effect of lipoxygenase inhibitor FLM 5011 on mitochondria ultrastructure of ischemic and reperfused cardiomyocytes.
Fitzl G; Winkler D; Wassilev G; Welt K
Exp Toxicol Pathol; 1999 May; 51(3):245-53. PubMed ID: 10334466
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of lipoxygenase (LOX) or of cyclooxygenase (COX) improves survival of rats in endotoxin shock.
Schaper U; Lueddeckens G; Förster W; Scheuch DW
Biomed Biochim Acta; 1988; 47(10-11):S282-5. PubMed ID: 3150270
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive therapy in the management of biopsy proven acute myocarditis.
Richardson PJ
Herz; 1985 Feb; 10(1):36-43. PubMed ID: 3979946
[TBL] [Abstract][Full Text] [Related]
9. A randomized, open-label, comparative, 6-month trial of oral ultra-low doses of antibodies to tumor necrosis factor-alpha and diclofenac in rheumatoid arthritis.
Dugina JL; Petrov VI; Babayeva AR; Martyushev-Poklad AV; Tcherevkova EV; Epstein OI; Sergeeva SA
Int J Tissue React; 2005; 27(1):15-21. PubMed ID: 15847101
[TBL] [Abstract][Full Text] [Related]
10. Lipoxygenase inhibitor FLM 5011, an effective protectant of myocardial microvessels against ischemia-reperfusion injury? An ultrastructural-morphometric study.
Welt K; Fitzl G; Mark B
Exp Toxicol Pathol; 2000 Mar; 52(1):27-36. PubMed ID: 10779150
[TBL] [Abstract][Full Text] [Related]
11. Biotransformation and toxicity of the lipoxygenase inhibitor 2-hydroxy-5-methyllaurophenone oxime (FLM 5011) on Hep G2 cells.
Mühlenfeld K; Langner A
Arch Pharm (Weinheim); 1998; 331(7-8):259-61. PubMed ID: 9747183
[TBL] [Abstract][Full Text] [Related]
12. [Acute episode].
Schölmerich J;
Z Gastroenterol; 2003 Jan; 41(1):27-30. PubMed ID: 12541170
[No Abstract] [Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
14. Potential anti-inflammatory effects of 5-lipoxygenase inhibition--exemplified by the leukotriene synthesis inhibitor BAY X 1005.
Müller-Peddinghaus R
J Physiol Pharmacol; 1997 Dec; 48(4):529-36. PubMed ID: 9444606
[TBL] [Abstract][Full Text] [Related]
15. Diclofenac/misoprostol: novel findings and their clinical potential.
Shield MJ
J Rheumatol Suppl; 1998 May; 51():31-41. PubMed ID: 9596552
[TBL] [Abstract][Full Text] [Related]
16. Renal colic in adults: NSAIDs and morphine are effective for pain relief.
Prescrire Int; 2009 Oct; 18(103):217-21. PubMed ID: 19882796
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis.
Pope JE; Prashker M; Anderson J
J Rheumatol; 2004 Jan; 31(1):140-9. PubMed ID: 14705233
[TBL] [Abstract][Full Text] [Related]
18. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.
Costagliola C; Parmeggiani F; Antinozzi PP; Caccavale A; Cotticelli L; Sebastiani A
Exp Eye Res; 2005 Nov; 81(5):610-5. PubMed ID: 15949795
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
20. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
